======================================================================
DATA ACQUISITION SUMMARY
Generated: 2026-02-03T17:25:30.000000
======================================================================

--------------------------------------------------
FDA FAERS DATA
--------------------------------------------------

Total records retrieved: 655

Records per drug:
  - semaglutide: 277 records
  - tirzepatide: 59 records
  - liraglutide: 319 records

Adverse event counts (from FDA counts endpoint):

  SEMAGLUTIDE:
    - thyroid_cancer: 12 reports
    - pancreatitis: 268 reports
    - gastroparesis: 0 reports

  TIRZEPATIDE:
    - thyroid_cancer: 4 reports
    - pancreatitis: 55 reports
    - gastroparesis: 1 reports

  LIRAGLUTIDE:
    - thyroid_cancer: 18 reports
    - pancreatitis: 304 reports
    - gastroparesis: 1 reports

Matched categories in fetched records:
  - thyroid_cancer: 33 records
  - pancreatitis: 622 records
  - gastroparesis: 2 records

Serious events in fetched records:
  - Serious: 610
  - Deaths: 18
  - Hospitalizations: 360

--------------------------------------------------
OPEN TARGETS SAFETY DATA
--------------------------------------------------

GLP1R (ENSG00000112164):
  Full Name: glucagon like peptide 1 receptor
  Safety Liabilities: 2
    - less weight gain (ClinPGx)
    - weight gain (ClinPGx)
  Genetic Constraint Scores: 3
    - syn: score=-0.093, oe=1.013 (not constrained)
    - mis: score=1.801, oe=0.767 (moderately constrained)
    - lof: score=0.986, oe=0.311 (HIGHLY CONSTRAINED - upper bin 1)

GIPR (ENSG00000010310):
  Full Name: gastric inhibitory polypeptide receptor
  Safety Liabilities: 3
    - weight gain (ClinPGx)
    - plasma insulin levels (ClinPGx)
    - plasma insulin levels and weight gain (ClinPGx)
  Genetic Constraint Scores: 3
    - syn: score=-0.191, oe=1.023 (not constrained)
    - mis: score=-1.176, oe=1.141 (not constrained)
    - lof: score=0.0, oe=1.321 (NOT constrained - upper bin 8)

Key Finding: GLP1R shows high loss-of-function constraint (oe=0.31),
indicating it is an essential gene with potential safety implications.
GIPR shows no constraint, suggesting more tolerance to genetic variation.

--------------------------------------------------
SUCCESS CRITERIA CHECK
--------------------------------------------------

[PASS] All drugs have FAERS records
[PASS] Open Targets data retrieved for both targets
[PASS] FAERS records fetched: 655
[PASS] Safety liabilities retrieved for GLP1R and GIPR
[PASS] Genetic constraint scores retrieved for both targets

All success criteria have been met.